AML3D LIMITED — Capital/Financing Update 2023

Mar 20, 2023

ASX Release 21 March 2023

==> picture [52 x 47] intentionally omitted <==

AML3D EXPANDS PRESENCE IN US DEFENCE INDUSTRY WITH ALLOY TESTING CONTRACT

HIGHLIGHTS

• US Department of Defence signs an alloy testing contract that expands AML3D’s US growth strategy.

• Alloy testing represents the next phase in embedding AML3D’s ARCEMY[® ] technology into the US Navy’s submarine industrial base.

• The contract follows the US Department of Defence’s purchase of a large scale ARCEMY[®] ‘X-Edition 6700’ 3D printing system to be installed in the Oak Ridge National Laboratory[1] .

AML3D Limited (ASX:AL3) (" AML3D " or " the Company ") is pleased to announce an expansion of its US Market scale-up strategy, with a new contract for an alloy characterisation and testing program to support the US Navy’s submarine industrial base. The contract has been signed with BlueForge Alliance (“BFA”), a non-profit, neutral convener and integrator supporting technology adoption and acceleration across the US defence sector in conjunction with the US Department of Defence.

The new contract is part of an ongoing expansion of AML3D’s strategic partnership with the US Navy. The alloy characterisation and testing program is intended to demonstrate that specific alloys that are 3D printed meet the manufacturing standards required to supply components to the US Navy’s submarine program. AML3D’s ARCEMY[®] systems are designed to produce industrial-scale components on-demand, at or near the point of need.

The material characterisation and testing contract is valued at approximately AUD$264,300. Whilst the value of the characterisation and testing contract is not material, the contract demonstrates AML3D is continuing to build momentum in the US market, the largest additive manufacturing market in the world and AML3D’s most important growth market. The work associated with this contract will be carried out at AML3D’s facility in Adelaide, South Australia. It will commence immediately and is expected to be completed within 8-10 weeks.

AML3D CEO Ryan Millar said:

“AML3D is excited to continue to develop its long-term, strategic partnership with the US Navy’s submarine industrial base. Our expansion in the US comes at a time of heightened interest in the potential of advanced manufacturing technologies to help meet increasing demand driven by the AUKUS alliance between the US, Australia and Britain. The alloy testing contract perfectly aligns with AML3D’s focus on the US defence, aviation and maritime sectors as drivers of growth. The alloy testing contract follows the sale, last month, of an ARCEMY[®] ‘X-Edition 6700’ system, via BFA, for use at the Oak Ridge National Laboratory in Tennessee, a key partner to the US Navy and other US global tier 1 clients. AML3D will continue to maximise the growth opportunities we see in the US by building out our North American sales team and capabilities, including establishing a value-added reseller network. This expansion into the US will result in AML3D being well positioned to access the opportunities that will be

1 AML3D Limited, AML3D Enters US Defence Industry with ARCEMY Sale, 1 February 2023

Page Page | 1

AML3D Limited (ASX:AL3) ACN 602 857 983 | Australian Patent 2019251514

ASX Release 21 March 2023

==> picture [52 x 47] intentionally omitted <==

created as a result of the AUKUS Alliance, both in the US and Australia, where we have an established advanced manufacturing and research and development base in Adelaide, home to the Osborne Naval Shipyard, Australia's largest naval shipbuilding hub.”

Share Purchase Plan

As announced on 2 March 2023, the Share Purchase Plan (‘SPP') opened on 13 March 2023, and is expected to close on Monday, 3 April 2023, unless extended or closed earlier at the discretion of the Company. The Board is pleased with the response to the SPP to date and encourages all Eligible Shareholders to read the SPP Offer Booklet lodged with ASX and sent to Eligible Shareholders on 13 March 2023, prior to submitting an application. If you have not received your application form, please contact the Company’s advisers on 1300 560 339 or +612 8011 0354 (from outside Australia).

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact

Ryan Millar

Hamish McEwin

Chief Executive Officer Chief Financial Officer AML3D Limited AML3D Limited T: +61 8 8258 2658 T: +61 8 8258 2658 E: investor@aml3d.com E: investor@aml3d.com

About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company’s patented Wire Additive Manufacturing (WAM®) process. WAM® combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY® industrial metal 3D printing systems. ARCEMY® uses WAM® to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY® is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.

Page Page | 2

AML3D Limited (ASX:AL3) ACN 602 857 983 | Australian Patent 2019251514